News | March 2, 2021

Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases RLYB212: A Novel Monoclonal HPA-1a Antibody for the Prevention of a Potentially Life-Threatening Rare Disease that Impacts Fetuses and Newborns...